Personalized Vaccine Upends Cancer Playbook

A cancer vaccine built from a patient’s own tumor just helped stop melanoma from coming back after surgery, according to new trial results from Merck and Moderna.

Quick Take

Merck and Moderna say their Phase 3 trial met its main goals for melanoma patients after surgery.
The personalized mRNA vaccine is paired with the immunotherapy drug Keytruda.
Earlier mid-stage data already showed a 44% drop in recurrence or death risk.
Moderna’s stock jumped sharply on the announcement, and regulators had already flagged the drug as a breakthrough.

A Late-Stage Trial Clears Its Biggest Hurdle

Merck and Moderna announced that their Phase 3 INTerpath-001 trial met both of its main goals in patients with completely removed stage IIB through IV melanoma. The vaccine, called intismeran autogene, cut the risk of cancer coming back and slowed its spread to distant parts of the body. Industry watchers called it a landmark result, since no personalized cancer vaccine had ever succeeded in a randomized late-stage trial before.

Melanoma is the deadliest form of skin cancer, and it kills roughly 8,500 Americans every year. Even after surgeons remove a tumor, the disease often returns because stray cancer cells can hide in the body. This trial targeted exactly that problem, testing whether a vaccine built from each patient’s own tumor could help the immune system hunt down those leftover cells before they spread.

How a Vaccine Gets Built From Your Own Cancer

The treatment works by sequencing a patient’s tumor to find its unique mutations, called neoantigens. Scientists then use those mutations to build a custom messenger RNA, or mRNA, vaccine meant to train the immune system to recognize and attack those specific cancer cells. It gets paired with Keytruda, an immunotherapy drug already approved to help the body fight several cancers.

This is not the platform’s first success. In an earlier mid-stage study known as KEYNOTE-942, patients with resected high-risk melanoma who got the vaccine plus Keytruda saw a 44% drop in the risk of recurrence or death compared to Keytruda alone. Follow-up data years later showed nearly 69% of combination patients stayed cancer-free, compared to about 49% on Keytruda by itself. The Food and Drug Administration (FDA) had already granted the combo breakthrough therapy status based on those earlier numbers.

Wall Street and Doctors Both Took Notice

Moderna’s shares surged after the companies released the topline results, more than doubling in a single trading session as investors bet on the vaccine’s path toward approval. Cancer researchers presenting five-year data at a major oncology meeting called the survival trend encouraging, noting the benefit held up even years after the original surgery.

Gavi, the vaccine alliance, described this as the first late-stage randomized trial of a personalized cancer vaccine to actually succeed, though it noted the full detailed findings had not yet been published in a medical journal. That is a normal part of how these announcements work. Companies release topline numbers first, and the complete dataset follows later through peer review and regulatory filings.

What Happens Next for Patients

Merck and Moderna are expected to bring these results to regulators as part of an approval application for melanoma patients who have had surgery but remain at high risk of recurrence. The companies are also running similar trials testing the same personalized vaccine platform in lung cancer, suggesting this approach could eventually stretch well beyond skin cancer if the melanoma data holds up under full review.

For patients facing a melanoma diagnosis today, this trial offers something rare in oncology: a treatment built specifically for their own tumor, not a one-size-fits-all drug. It’s a genuinely encouraging step, built on real trial data rather than hype, and it deserves the attention it’s getting from both doctors and investors.